A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation

Journal of Virology

Volumn 77, Issue 10, 2003, Pages 5685-5693

  García Lerma, J Gerardo ^a,c   MacInnes, Hamish ^a   Bennett, Diane ^b   Reid, Patrick ^a   Nidtha, Soumya ^a   Weinstock, Hillard ^b   Kaplan, Jonathan E ^a,b   Heneine, Walid ^a  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RNA DIRECTED DNA POLYMERASE; STAVUDINE; ZIDOVUDINE;

ARTICLE; BIOASSAY; CHEMICAL ANALYSIS; CONTROLLED STUDY; ENZYME ASSAY; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; PHENOTYPE; PRIORITY JOURNAL; REVERTANT; VIRUS CHARACTERIZATION; VIRUS REPLICATION; VIRUS RESISTANCE; WILD TYPE;

ANTI-HIV AGENTS; CELL LINE; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE; VIRUS CULTIVATION; ZIDOVUDINE;

EID: 0038033098     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.77.10.5685-5693.2003     Document Type: Article

References (46)

1. Arion, D., G. Borkow, Z. Gu, M. A. Wainberg, and M. A. Parniak. 1996. The K65R mutation confers increased DNA polymerase processivity to HIV-1 reverse transcriptase. J. Biol. Chem. 271:19860-19864.
2. Bazmi, H. Z., J. L. Hammond, S. C. Cavalcanti, C. K. Chu, R. F. Schinazi, and J. W. Mellors. 2000. In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibilily to (-)-β-D-dioxolane-guanosine and suppress resistance to 3′-azido- 3′-deoxythymidine. Antimicrob. Agents Chemother. 44:1783-1788.
3. Boucher, C. A. B., N. Cammack, P. Scipper, R. Schuurman, P. Rouse, M. A. Wainberg, and J. M. Cameron. 1993. High-level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 37:2231-2234.
4. D'Aquila, R. T., J. M. Schapiro, F. Brun-Vezinet, B. Clotet, B. Conway, L. M. Demeter, R. M. Grant, V. A. Johnson, D. R. Kuritzkes, C. Loveday, R. W. Shafer, and D. D. Richman. 2002. Drug resistance mutations in HIV-1. Top. HIV Med. 10:11-15.
5. de Mendoza, C., V. Soriano, C. Briones, O. Gallego, P. Barreiro, A. Alvarez, and J. González-Lahoz. 2000. Emergence of zidovudine resistance in HIV-infected patients receiving stavudine. J. Acquir. Immune Defic. Syndr. 23: 279-281.
6. de Ronde, A., M. van Dooren, E. de Rooij, B. van Gemen, J. Lange, and J. Goudsmit. 2000. Infection by zidovudine-resistant HIV-1 compromises the virological response to stavudine in a drug-naive patient. AIDS 14:2632-2633.
7. Foli, A., K. M. Sogocio, B. Anderson, M. Kavlick, M. W. Saville, M. A. Wainberg, Z. Gu, J. M. Cherrington, H. Mitsuya, and R. Yarchoan. 1996. In vitro selection and molecular characterization of human immunodeficiency virus type 1 with reduced sensitivity to 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA). Antivir. Res. 32:91-98.
8. García-Lerma, J. G., P. J. Gerrish, A. C. Wright, S. H. Qari, and W. Heneine. 2000. Evidence of a role for the Q151L mutation and the viral background in development of multiple dideoxynucleoside-resistant human immunodeficiency virus type 1. J. Virol. 74:9339-9346.
9. García-Lerma, J. G., S. Nidtha, K. Blumoff, H. Weinstock, and W. Heneine. 2001. Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons. Proc. Natl. Acad. Sci. USA 98:13907-13912.
10. Goudsmit, J., A. de Ronde, E. de Rooij, and R. de Boer. 1997. Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215. J. Virol. 71:4479-4484.
11. Goudsmit, J., A. de Ronde, D. D. Ho, and A. S. Perelson. 1996. Human immunodeficiency virus fitness in vivo: calculations based on single zidovudine resistance mutation at codon 215 of reverse transcriptase J. Virol. 70:5662-5664.
12. Gu, Z., R. S. Fletcher, E. J. Arts, M. A. Wainberg, and M. A. Parniak. 1994. The K65R mutant reverse transcriptase of HIV-1 cross-resistant to 2′,3′-dideoxycytidine, 2′,3′-dideoxy-3′-thiacytidine, and 2′,3′-dideoxyinosine shows reduced sensitivity to specific dideoxynucleoside triphosphate inhibitors in vitro J. Biol. Chem. 269:28118-28122.
13. Gu, Z., Q. Gao, H. Fang, M. A. Parniak, B. G. Brenner, and M. A. Wainberg. 1994. Identification of novel mutations that confer drug resistance in the human immunodeficiency virus polymerase gene. Leukemia 8(Suppl. 1): S166-S169.
14. Gu, Z., Q. Gao, H. Fang, H. Salomon, M. A. Parniak, E. Goldberg, J. Cameron, and M. A. Wainberg. 1994. Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2′,3′-dideoxycytidine and 2′,3′-dideoxy-3′-thiacytidine Antimicrob. Agents Chemother. 38:275-281.
15. Hertogs, K., M. de Bethune, V. Miller, T. Ivens, P. Schel, A. van Cauwenberge, C. Van den Eynde, V. Van Gerwen, H. Azijn, M. Van Houtte, F. Peeters, S. Staszewski, M. Conant, S. Bloor, S. Kemp, B. Larder, and R. Pauwels. 1998. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob. Agents Chemother. 42:269-276.
16. Johnson, V. A., C. J. Petropoulos, C. R. Woods, J. D. Hazelwood, N. T. Parkin, C. D. Hamilton, and S. A. Fiscus. 2001. Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant. J. Infect. Dis. 183:1688-1693.
17. Lacey, S. F., and B. A. Larder. 1994. Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2′,3′-didehydro-2′,3′-dideoxythymidine in cell culture. Antimicrob. Agents Chemother. 38:1428-1432.
18. Larder, B. A., K. E. Coates, and S. D. Kemp. 1991. Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture J. Virol. 65:5232-5236.
19. Larder, B. A., and S. D. Kemp. 1989. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246: 1155-1157.
20. Lin, P. F., C. J. González, B. Griffith, G. Friedland, V. Calvez, F. Ferchal, R. F. Schinazi, D. H. Shepp, A. B. Ashraf, M. A. Wainberg, V. Soriano, J. W. Mellors, and R. J. Colonno. 1999. Stavudine resistance: an update on susceptibility following prolonged therapy. Antivir. Ther. 4:21-28.
21. Lin, P. F., H. Samanta, R. E. Rose, A. K. Patick, J. Trimble, C. M. Bechtold, D. R. Revie, N. C. Khan, M. E. Federici, H. Li, A. Lee, R. E. Anderson, and R. J. Colonno. 1994. Genotypic and phenotypic analysis of human immuno-deficiency virus type 1 isolates from patients on prolonged stavudine therapy J. Infect. Dis. 170:1157-1164.
22. Maxeiner, H. G., W. Keulen, R. Schuurman, M. Bijen, L. de Graaf, A. van Wijk, N. Back, M. W. Kline, C. A. Boucher, and M. Nijhuis. 2002. Selection of zidovudine resistance mutations and escape of human immunodeficiency virus type 1 from antiretroviral pressure in stavudine-treated pediatric patients J. Infect. Dis. 185:1070-1076.
23. Meyer, P. R., S. E. Matsuura, A. M. Mian, A. G. So, and W. A. Scott. 1999. A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol. Cell 4:35-43.
24. Meyer, P. R., S. E. Matsuura, A. G. So, and W. A. Scott. 1998. Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism Proc. Natl. Acad. Sci. USA. 95:13471-13476.
25. Meyer, P. R., S. E. Matsuura, R. F. Schinazi, A. G. So, and W. A. Scott. 2000. Differential removal of thymidine nucleotide analogues from blocked DNA chains by human immunodeficiency virus reverse transcriptase in the presence of physiological concentrations of 2′-deoxynucleoside triphosphates. Antimicrob. Agents Chemother. 44:3465-3472.
26. Miller, M. D., N. A. Margot, P. D. Lamy, M. D. Fuller, K. E. Anton, A. S. Mulato, and J. M. Cherrington. 2001. Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: genotypic and phenotypic analyses of study GS-96-408. J. Acquir. Immune Defic. Syndr. 27:450-458.
27. Moore, J. D., G. Valette, A. Darque, X.-J. Zhou, and J.-P. Sommadossi. 2000. Simultaneous quantitation of the 5′-triphosphate metabolites of zidovudine, lamivudine, and stavudine in peripheral mononuclear blood cells of HIV infected patients by high-performance liquid chromatography tandem mass spectrometry. J. Am. Soc. Mass Spectrom. 11:1134-1143.
28. Moyle, G. J., and B. G. Gazzard. 2001. Differing reverse transcriptase mutation patterns in individuals experiencing viral rebound on first-line regimens with stavudine/didanosine and stavudine/lamivudine. AIDS 15:799-800.
29. Pauwels, R., J. Balzarini, M. Baba, R. Snoeck, D. Schols, P. Herdewijn, J. Desmyter, and E. de Clercq. 1988. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 20:309-321.
30. Pellegrin, I., J. Izopet, J. Reynes, M. Denayrolles, B. Montes, J. L. Pellegrin, P. Massip, J. Puel, H. Fleury, M. Segondy, et al. 1999. Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy. AIDS 13:1705-1709.
31. Petropoulos, C. J., N. T. Parkin, K. L. Limoni, Y. S. Lie, T. Wrin, W. Huang, H. Tian, D. Smith, G. A. Winslow, D. J. Capon, and J. M. Whitcomb. 2000. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 44:920-928.
32. Picard, V., E. Angelini, A. Maillard, E. Race, F. Clavel, G. Chene, F. Ferchal, and J. M. Molina. 2001. Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine. J. Infect. Dis. 184:781-784.
33. Reed, L. J., and H. Muench. 1938. A simple method for estimating fifty percent end points. Am. J. Hyg. 27:493-497.
34. Riva, C., M. Violin, A. Cozzi-Lepri, R. Velleca, A. Bertoli, P. Vigano, L. Minoli, A. Orani, G. Rizzardini, T. Zauli, C. F. Perno, A. d'Arminio-Monforte, and C. Balotta for the I.Co.N.A. Study Group. 2002. Transmitted virus with substitutions at position 215 and risk of virological failure in antiretroviral-naive patients starting highly active antiretroviral therapy. Antiviral Ther. 7:S136.
35. Roge, B. T., T. L. Katzenstein, N. Obel, H. Nielsen, O. Kirk, C. Pedersen, L. Mathisen, J. Lundgren, and J Gerstoft. K65R with and without S68 - a new resistance profile in vivo detected in most patients failing abacavir, didanosine, and stavudine. Antivir. Ther., in press.
36. Ross, L., K. Henry, D. Paar, P. Salvato, M. Shaefer, R. Fisher, Q. Liao, and M. St Clair. 2001. Thymidine-analog and multi-nucleoside resistance mutations are observed in both zidovudine-naive and zidovudine-experienced subjects with viremia after treatment with stavudine-containing regimens. J. Hum. Virol. 4:217-222.
37. Ross, L., A. Scarsella, S. Raffanti, K. Henry, S. Becker, R. Fisher, Q. Liao, A. Hirani, N. Graham, M. St Clair, and J. Hernandez for the NZT40012 Study Team. 2001. Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine-naive patients experiencing viremia on stavudine-containing regimens. AIDS Res. Hum. Retrovir. 17:1107-1115.
38. Schmit, J. C., K. Van Laethem, L. Ruiz, P. Hermans, S. Sprecher, A. Sonnerborg, M. Leal, T. Harrer, B. Clotet, V. Arendt, E. Lissen, M. Witvrouw, J. Desmyter, E. de Clercq, and A. M. Vandamme. 1998. Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries. AIDS 12:2005-2015.
39. Schmit, J. C., J. Cogniaux, P. Hermans, C. Van Vaeck, S. Sprecher, B. Van Remoortel, M. Witvrouw, J. Balzarini, J. Desmyter, E. de Clercq, and A. M. Vandamme. 1996. Multiple drug resistance to nucleoside analogs and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain. J. Infect. Dis. 174:962-968.
40. Scott, W. A. 2001. The enzymatic basis for thymidine analogue resistance in HIV-1. AIDS Rev. 3:194-200.
41. Shah, F. S., K. A. Curr, M. E. Hamburgh, M. Parniak, H. Mitsuya, J. G. Arnez, and V. R. Prasad. 2000. Differential influence of nucleoside analogresistance mutations K65R and L74V on the overall mutation rate and error specificity of human immunodeficiency virus type 1 reverse transcriptase. J. Biol. Chem. 275:27037-27044.
42. Shulman, N. S., R. A. Machekano, R. W. Shafer, M. A. Winters, A. R. Zolopa, S. H. Liou, M. Hughes, D. A. Katzenstein, and the AIDS Clinical Trials Group 302 Study Team. 2001. Genotypic correlates of a virologic response to stavudine after zidovudine monotherapy. J. Acquir. Immune Defic. Syndr. 27:377-380.
43. Tisdale, N. S., D. Kemp, N. R. Parry, and B. A. Larder. 1993. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of the reverse transcriptase. Proc. Natl. Acad. Sci. USA 90:5653-5656.
44. Vandamme, A. M., M. Witvrouw, C. Pannecouque, J. Balzarini, K. Van Laethem, J. C. Schmit, J. Desmyter, and E. de Clercq. 1999. Evaluating clinical isolates for their phenotypic and genotypic resistance against anti-HIV drugs, p. 223-258. In J. Kinchington and R. F. Schinazi (ed.), Methods in molecular medicine: antiviral chemotherapy protocols, vol. 24. Humana Press Inc., Totowa, N.J.
45. Wainberg, M. A., M. D. Miller, Y. Quan, H. Salomon, A. S. Mulato, P. D. Lamy, N. A. Margot, K. E. Anton, and J. M. Cherrington. 1999. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir. Ther. 4:87-94.
46. Winters, M. A., K. L. Coolley, Y. A. Girard, D. J. Levee, H. Hamdan, R. W. Shafer, D. A. Katzenstein, and T. C. Merigan. 1998. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. J. Clin. Investig. 102: 1769-1775.